Three years of experience: The italian registry and safety data update

Neurological Sciences

Volumn 31, Issue SUPPL. 3, 2010, Pages

  Mancardi, G L ^a,b   Tedeschi, G ^b   Amato, M P ^b   D'Alessandro, R ^b   Drago, F ^b   Milanese, C ^b   Popoli, P ^b   Rossi, P ^b   Savettieri, G ^b   Tola, M R ^b   Comi, G ^c   Pozzilli, C ^d   Bertolotto, A ^e   Marrosu, M G ^f   Grimaldi, L M E ^g   Laroni, A ^a   Vanacore, N ^b   Covezzoli, A ^h   De Rosa, M ^h   Piccinni, C ⁱ   Montanaro, N ⁱ   Periotto, L ^j   Iommelli, R ^j   Tomino, C ^j   Provinciali, L ^b   more..

^a UNIVERSITY OF GENOA   (Italy)

^b Tavolo Neurologico AIFA   (Italy)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

^f UNIVERSITY OF CAGLIARI   (Italy)

^g AO Villa Sofia CTO   (Italy)

^h CINECA   (Italy)

ⁱ UNIVERSITY OF BOLOGNA   (Italy)

^j AIFA   (Italy)

more..

Author keywords

Multiple sclerosis; Natalizumab; Pharmacovigilance; Surveillance program

Indexed keywords

MONOCLONAL ANTIBODY; NATALIZUMAB;

ADULT; ARTICLE; COMPARATIVE STUDY; FEMALE; HUMAN; ITALY; MALE; MULTIPLE SCLEROSIS; POSTMARKETING SURVEILLANCE; REGISTER; STATISTICS;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; ITALY; MALE; MULTIPLE SCLEROSIS; PRODUCT SURVEILLANCE, POSTMARKETING; REGISTRIES;

EID: 82455185180     PISSN: 15901874     EISSN: 15903478     Source Type: Journal    
DOI: 10.1007/s10072-010-0356-8     Document Type: Conference Paper

References (3)

1. Mancardi GL, Amato MP, D'Alessandro R, Drago F, Milanese C, Popoli P, Provinciali L, Rossi P, Savettieri G, Tedeschi G, Tola MR, Vanacore N, Covezzoli A, De Rosa M, Piccinni C, Montanaro N, Periotto L, Addis A, Martini N (2008) Natalizumab: a country-based pharmacovigilance program. Neurol Sci 29(Suppl 2):S235-S237
2. Tedeschi G, Amato MP, D'Alessandro R, Drago F, Milanese C, Popoli P, Rossi P, Savettieri G, Tola MR, Vanacore N, Covezzoli A, De Rosa M, Comi G, Pozzilli C, Bertolotto A, Marrosu MG, Grimaldi LM, Piccinni C, Montanaro N, Periotto L, Iommelli R, Addis A, Martini N, Provinciali L, Mancardi GL (2009) The pharmacovigilance program on natalizumab in Italy: 2 years of experience. Neurol Sci 30(Suppl 2):S163-S165
3. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW (2006) AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 354(9): 899-910